RESEARCH BRIEF
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers ............. 686
Précis: Patients with NRG1-rearranged tumors may be more sensitive to therapies targeting ERBB3 than ERBB2, and the presence of NRG1 fusions in multiple tumor types supports a basket trial approach to evaluate ERBB3 inhibitors.
See commentary, p. 676

RESEARCH ARTICLES
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma ............. 696
Précis: EGFR amplifications were identified in 5% of patients with gastroesophageal adenocarcinoma, and anti-EGFR therapy achieved responses in 4 of 7 patients with EGFR amplification, although various resistance mechanisms emerged.
See commentary, p. 679

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer ............. 714
Précis: The spectrum of ALK resistance mutations to the third-generation ALK inhibitor lorlatinib were identified by an in vitro mutagenesis screen and in clinical specimens from patients with ALK-positive lung cancer.
Genetic Mechanisms of Immune Evasion in Colorectal Cancer ............... 730
Précis: Analysis of 1,211 colorectal tumors found that MSI-H tumors have a higher frequency of mutations associated with immunoediting and both MSI-H and non-hypermutated tumors have WNT activating mutations that promote immune exclusion.

Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates ............... 750
Précis: A nonhuman primate model of B cell–targeted CAR T-cell immunotherapy recapitulates and provides insight into human CAR T-cell–mediated neurotoxicity and cytokine release syndrome.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth ............ 764
Précis: Pik3ca mutations are sufficient to cause prostate tumorigenesis in mice and can cooperate with Pten loss to accelerate disease progression and resistance to androgen deprivation therapy.

See commentary, p. 682